This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
We are committed to protecting the future commercial value of our innovative PH-HFpEF treatment,” said Chris Giordano , President & Chief Executive Officer of Tenax Therapeutics. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,
Increasing ketone supply to the heart in mice with heartfailure with preservedejectionfraction (HFpEF) allowed their hearts to utilize more ketones and produce more energy, according to preliminary research presented today at the American Heart Association's Basic Cardiovascular Sciences Scientific Sessions 2024.
Introduction The diagnostic and therapeutic arsenal for heartfailure with preservedejection (HFpEF) has expanded. We; therefore, evaluated the efficacy of an existing dedicated HFpEF clinic to find innovative ways to design a more comprehensive model tailored to the modern era of HFpEF.
Featured topics will include in-depth sessions covering non-statin lipid lowering therapies, heartfailure with preservedejectionfraction, viability, imaging modalities for the assessment of coronary artery disease, and antiplatelet therapy after coronary stenting. 24 news here.
In heartfailure with reduced ejectionfraction and heartfailure with preservedejectionfraction, profound cellular and molecular changes have recently been documented in the failing myocardium.These changes include altered calcium handling and metabolic efficiency of the cardiac myocyte, reactivation of the fetal gene program, changes in the electrophysiological (..)
May be, it will come soon in the innovative lanes of cardiology. Shah, author of Atrial Shunt Device Effects on Cardiac Structure and Function in HeartFailure With PreservedEjectionFraction: The REDUCE LAP-HF II Randomized Clinical Trial. Probably in the thin membranous area. Interview with Sanjiv J.
ET Murphy Ballroom 4 Comparison of an "Inclisiran First" Strategy with Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes Once-weekly Semaglutide in Patients with HeartFailure With PreservedEjectionFraction, (..)
Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heartfailure (HF) with a left ventricular ejectionfraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).
Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heartfailure (HF) with a left ventricular ejectionfraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).
From breakthrough medications to innovative technologies, there is a lot for cardiometabolic clinicians professionals to celebrate. These findings strengthen the case for broader utilization of finerenone in heartfailure management. This year, the cardiometabolic health community has witnessed remarkable advancements.
We report from the 19 th Annual Scientific Meeting of the Cardiorenal Forum held in London on 4 th October 2024, which served as a dynamic platform for experts in cardiology, diabetes, and renal medicine to converge and exchange the latest insights on managing heart and kidney failure.
Attendees, including hundreds of health professionals, gained access to the latest knowledge and developments in the field, from exclusive insights from one of the foremost authorities on atherosclerosis, Dr. Peter Libby, to innovations like new therapeutic agents and exciting advancements in renal protection.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content